Pemvidutide vs Survodutide vs Retatrutide: The Glucagon-Arm Comparison

Why glucagon is suddenly the interesting receptor

Until recently, glucagon was treated almost entirely as the hormone that raises blood sugar — the counterpart to insulin, something a diabetes drug would want to suppress, not activate. The newer view: glucagon has additional metabolic effects that, when activated alongside GLP-1's appetite suppression, produce a different and deeper weight-loss profile than GLP-1 alone or GLP-1/GIP dual agonism.

Specifically, glucagon receptor activation produces:

• Increased energy expenditure — the body burns more calories at rest.
• Hepatic lipid breakdown — stored liver fat is mobilized and used for energy.
• Some additional satiety — contributes to appetite reduction beyond GLP-1's central effects.

The glucose-raising effect of glucagon still applies, but it is overwhelmed by the strong glucose-lowering effect of the co-activated GLP-1 arm. Three Phase 3 obesity drugs now exploit this glucagon-arm strategy.

Pemvidutide — Altimmune's MASH-leaning bet

Pemvidutide is a GLP-1 / glucagon dual receptor agonist developed by Altimmune, a small US biotech. Phase 2 data showed approximately 15.6% mean weight loss at 48 weeks at the highest dose, with particularly strong liver fat reduction. Altimmune has positioned pemvidutide primarily as a MASH (metabolic dysfunction-associated steatohepatitis) drug rather than a pure obesity drug — the MOMENTUM-MASH Phase 3 trial is the lead program, with obesity as a parallel indication.

The honest framing: pemvidutide's weight-loss magnitude is meaningful but smaller than survodutide's or retatrutide's. Its differentiation is the MASH focus and the smaller-company positioning that allows a sharper indication strategy than Boehringer or Lilly would pursue.

Survodutide — Boehringer / Zealand's broader bet

Survodutide is a GLP-1 / glucagon dual receptor agonist developed by Boehringer Ingelheim in partnership with Zealand Pharma. Phase 2 showed approximately 19% mean weight loss at 46 weeks at the highest dose, with substantial liver fat reduction. The Phase 3 SYNCHRONIZE program runs across obesity, type 2 diabetes, and MASH indications.

Survodutide sits in the middle position of the three: deeper weight loss than pemvidutide, MASH-focused like pemvidutide, but with a major pharmaceutical sponsor's reach. See our dedicated survodutide explainer for the full picture.

Retatrutide — Eli Lilly's triple-agonist bet

Retatrutide is different from pemvidutide and survodutide in one key way: it adds the GIP receptor to the GLP-1 / glucagon combination. This makes it a triple agonist rather than a dual. The Phase 2 weight loss — approximately 24% at 48 weeks — is the deepest ever recorded for a GLP-1-class drug, suggesting the extra GIP arm adds meaningful magnitude.

Retatrutide's Phase 3 TRIUMPH program is also broader, covering obesity, diabetes, sleep apnea, and cardiovascular outcomes alongside MASH. Eli Lilly is the largest GLP-1 company in the world by revenue and brings the most clinical infrastructure to a Phase 3 program. See our retatrutide plain-English explainer for the mechanism in detail.

Head-to-head comparison

What the dual-vs-triple question actually tests

The three drugs together effectively run a natural experiment on a real scientific question: does adding the GIP arm to GLP-1 + glucagon meaningfully deepen weight loss, or is it incremental noise that adds side-effect burden without proportionate magnitude?

The Phase 2 magnitudes suggest the GIP arm is contributing — retatrutide's 24% vs the duals' 16-19% — but Phase 2 trials are small and the difference within the dual category (pemvidutide 16%, survodutide 19%) is also substantial without any mechanism difference. Phase 3 readouts will tell us whether the GIP contribution is robust at scale or if dose-titration and patient selection account for most of the difference.

The MASH dimension — a separate competition

For MASH specifically, the picture changes from a pure weight-loss comparison. All three drugs produce meaningful liver fat reduction, but the indication strategy differs:

• Pemvidutide is built around MASH — it is Altimmune's lead indication.
• Survodutide pursues MASH and obesity as parallel indications with Boehringer / Zealand's scale.
• Retatrutide has MASH as one of several indications but is not its primary positioning.

The first FDA-approved MASH drug was resmetirom (2024) — a thyroid hormone receptor agonist, not a GLP-1-class drug. The three glucagon-arm GLP-1 drugs represent a different therapeutic strategy for the same disease, with pemvidutide and survodutide most directly competing in that space.

The honest read

If the question is maximum weight loss, retatrutide will likely be the answer when it reaches market — unless the Phase 3 readout disappoints. If the question is MASH-specific treatment with strong weight loss as a secondary benefit, survodutide and pemvidutide are the closer competitors. If the question is which to choose today, the answer is none of them — all three are 1-2+ years from FDA approval, and currently-available GLP-1 drugs (semaglutide, tirzepatide) cover most patients well.

The deeper point: by 2028, the obesity drug class will probably look meaningfully different from today's semaglutide-or-tirzepatide choice, with MASH-specific options, deeper-magnitude triple agonists, and the glucagon arm as a standard rather than novel feature. These three drugs together are the leading edge of that transition.